Meeting
2015 ASCO Annual Meeting
Efficacy and safety of first-line palbociclib plus letrozole compared with letrozole alone in patients aged ≥ 65 years with estrogen receptor-positive, HER2-negative advanced breast cancer: A subgroup analysis by age of the PALOMA-1/TRIO-18 trial.
Authors
John Crown
Irish Cooperative Oncology Research Group, Dublin, Ireland
John Crown , Richard S. Finn , Johannes Ettl , Katalin Boer , Ravi Patel , Anu Thummala , Sophia Randolph , Sindy Kim , Xin Huang , Sashi Nadanaciva , Patrick Schnell , Cynthia Huang Bartlett , Dennis J. Slamon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00721409
Citation
J Clin Oncol 33, 2015 (suppl; abstr 571)
DOI
10.1200/jco.2015.33.15_suppl.571
Abstract #
571
Poster Bd #
59
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Clinical efficacy and safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment in patients (pts) with ER+ and HER2- advanced breast cancer (ABC) who have not received any systemic treatment (ST): A subgroup analysis of PALOMA-1/TRIO-18.
First Author: Richard S. Finn
Poster
2015 ASCO Annual Meeting
Long-term safety profile of palbociclib (P) in combination with letrozole (L) as first-line treatment for postmenopausal patients with ER+ and HER2- advanced breast cancer (ABC) (PALOMA-1/TRIO-18).
First Author: Dennis J. Slamon
First Author: Richard S. Finn
Poster
2022 ASCO Annual Meeting
Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Mafalda Oliveira